A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
Middleton G, Robbins HL, Fletcher P, Savage J, Mehmi M, Summers Y, Greystoke A, Steele N, Popat S, Jain P, Spicer J, Cave J, Shaw P, Gilligan D, Power D, Fennell D, Bajracharya M, McBride DJ, Maheswari U, Frankell AM, Swanton C, Beggs AD, Billingham L.
Middleton G, et al. Among authors: robbins hl.
NPJ Precis Oncol. 2025 Mar 11;9(1):67. doi: 10.1038/s41698-025-00838-4.
NPJ Precis Oncol. 2025.
PMID: 40069402
Free PMC article.